Results 61 to 70 of about 3,471,294 (187)

Contribution of PER-Type and NDM-Type β-Lactamases to Cefiderocol Resistance in Acinetobacter baumannii. [PDF]

Antimicrob Agents Chemother, 2021
Poirel L, Sadek M, Nordmann P.
europepmc   +2 more sources

Occurrence of KPC-71 or the presence of NDM combined with a high expression of <i>bla</i>_SHV contributes to low-level cefiderocol resistance in carbapenem-resistant <i>Klebsiella pneumoniae</i> in China. [PDF]

Microbiol Spectr
Hong H, Liu Y, Fan L, Shi B, Luo R, Xi C, Yang Z, Yang W, Zeng X, Wei D, Liu Y.   +10 more
europepmc   +2 more sources

Population Analysis of Escherichia coli Sequence Type 361 and Reduced Cefiderocol Susceptibility, France

Emerging Infectious Diseases, 2023
Cefiderocol resistance is increasingly reported in New Delhi metallo-β-lactamase–producing Enterobacterales. Genomic and phenotypic analysis of Escherichia coli sequence type 361, a primary clone causing carbapenemase spread in France, revealed ...
Agnès B. Jousset, Laura Bouabdallah, Aurélien Birer, Isabelle Rosinski-Chupin, Jean-François Mariet, Saoussen Oueslati, Cécile Emeraud, Delphine Girlich, Philippe Glaser, Thierry Naas, Rémy A. Bonnin, Laurent Dortet   +11 more
doaj   +1 more source

Proteomic and Transcriptomic Analyses Indicate Reduced Biofilm-Forming Abilities in Cefiderocol-Resistant Klebsiella pneumoniae

Frontiers in Microbiology, 2022
The advent of cefiderocol provides hope for the clinical treatment of multi-drug resistant gram-negative bacteria (GNB), especially those with carbapenem resistance.
Jinfeng Bao, Jinfeng Bao, Jinfeng Bao, Lu Xie, Yating Ma, Ran An, Bing Gu, Bing Gu, Chengbin Wang   +8 more
doaj   +1 more source

In Vitro Activity of Cefiderocol on Multiresistant Bacterial Strains and Genomic Analysis of Two Cefiderocol Resistant Strains

Antibiotics, 2023
Cefiderocol is a new siderophore cephalosporin that is effective against multidrug-resistant Gram-negative bacteria, including carbapenem-resistant strains. The aim of this study was to evaluate the activity of this new antimicrobial agent against a collection of pathogens using broth microdilution assays and to analyze the possible mechanism of ...
Padovani M., Bertelli A., Corbellini S., Piccinelli G., Gurrieri F., De Francesco M. A.   +5 more
openaire   +4 more sources

In vitro activity of cefiderocol against Gram-negative bacterial pathogens in Germany

Journal of Global Antimicrobial Resistance, 2022
: Objectives: Widespread antimicrobial resistance in Gram-negative bacteria (GNB), particularly carbapenem resistance, represents a major clinical challenge.
Philipp Thelen, Anne Santerre Henriksen, Christopher Longshaw, Yoshinori Yamano, Ben Caldwell, Axel Hamprecht   +5 more
doaj   +1 more source

Metallo-sideromycin as a dual functional complex for combating antimicrobial resistance

Nature Communications, 2023
The rapid emergence of antimicrobial resistance (AMR) pathogens highlights the urgent need to approach this global burden with alternative strategies. Cefiderocol (Fetroja®) is a clinically-used sideromycin, that is utilized for the treatment of severe ...
Chenyuan Wang, Yushan Xia, Runming Wang, Jingru Li, Chun-Lung Chan, Richard Yi-Tsun Kao, Patrick H. Toy, Pak-Leung Ho, Hongyan Li, Hongzhe Sun   +9 more
doaj   +1 more source

Synergistic Effect of Clinically Available Beta-Lactamase Inhibitors Combined with Cefiderocol against Carbapenemase-Producing Gram-Negative Organisms

Antibiotics, 2022
The role of β-lactamases in reduced susceptibility or resistance to cefiderocol has been supported by recent reports. The purpose of this study was to investigate the in vitro impact of clinically available β-lactamase inhibitors on cefiderocol activity ...
Gabriele Bianco, Paolo Gaibani, Sara Comini, Matteo Boattini, Giuliana Banche, Cristina Costa, Rossana Cavallo, Patrice Nordmann   +7 more
doaj   +1 more source

P-1197. NDM-5 and Siderophore Receptor Mutations Drive High Level Cefiderocol Resistance in Klebsiella pneumoniae: A Case Series [PDF]

Open Forum Infect Dis
Michelle Potter, Wajih Askar, Gerardo F Gomez-Abundis, Kent Carpenter, Emir Kobic   +4 more
europepmc   +3 more sources

Clinical Outcome of Cefiderocol for Infections with Carbapenem-Resistant Organisms

Antibiotics, 2023
Cefiderocol is a novel cephalosporin recently approved by the FDA to aid clinicians in the fight against multidrug-resistant (including carbapenem-resistant) gram-negative organisms. The primary objective of this study is to evaluate the 14- and 28-day mortality associated with cefiderocol.
Monirul I. Sajib, Melinda Monteforte, Roderick Go   +2 more
openaire   +3 more sources